4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of$ 0.84. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.38%. A quarter ago, it was expected that this company would post a loss of$ 0.80 per share when it actually produced a loss of $0.90, delivering a surprise of -12.50%.Over the last four quarters, the com ...